EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of SCN1Aand SCN2A gene polymorphisms on the efficacy of valproic acid treatment in Chinese children with epilepsy

Zejun Bao, Huanzhou Li, Jing Hu, Ru Zhao, Ling Yan, Aibin Zheng iD

PLOS ONE · 05.06.2024 · 19 (6) · e0304869

DOI: 10.1371/journal.pone.0304869 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 05.06.2024. Verfasst von Zejun Bao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Changzhou Children's Hospital Affiliated to Nantong University, Changzhou, Jiangsu, China. Hauptthemen laut MEDLINE: NAV1.1 Voltage-Gated Sodium Channel, Valproic Acid, NAV1.2 Voltage-Gated Sodium Channel, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2021 Changzhou Key R&D Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Epilepsy patients exhibit considerable differences in their response to sodium valproate (VPA) therapy, a phenomenon that might be attributed to individual genetic variances. The role of genetic variations, specifically in sodium channels encoded by SCN1A and SCN2A genes, in influencing the effectiveness of VPA in treating epilepsy is still debated. This research focuses on examining the impact of these genetic polymorphisms on the efficacy of VPA therapy among pediatric epilepsy patients in China.

Methods

Five single nucleotide polymorphisms (SNPs), including SCN1A (rs10188577, rs2298771, rs3812718) and SCN2A (rs2304016, rs17183814), were genotyped in 233 epilepsy patients undergoing VPA therapy. The associations between genotypes and the antiepileptic effects of VPA were assessed, with 128 patients categorized as VPA responders and 105 as VPA non-responders.

Results

In the context of VPA monotherapy, SCN1A rs2298771 and SCN2A rs17183814 were found to be significantly associated with VPA response ( P < 0.05).

Conclusion

Our study suggests the findings of this investigation indicate that the polymorphisms SCN1A rs2298771 and SCN2A rs17183814 could potentially act as predictive biomarkers for the responsiveness to VPA among Chinese epilepsy patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NAV1.1 Voltage-Gated Sodium ChannelValproic AcidNAV1.2 Voltage-Gated Sodium ChannelPolymorphism, Single NucleotideEpilepsyAnticonvulsantsHumansChildMaleFemaleChild, PreschoolChinaAdolescentTreatment OutcomeGenotypeInfantEast Asian People

Substanzen

NAV1.1 Voltage-Gated Sodium ChannelValproic AcidSCN1A protein, humanNAV1.2 Voltage-Gated Sodium ChannelSCN2A protein, humanAnticonvulsants

Autor:innen und Institutionen

  • Changzhou Children's Hospital Affiliated to Nantong University, Changzhou, Jiangsu, China.

ORCID-Profile: Aibin Zheng

Förderung

  • 2021 Changzhou Key R&D Program

Zitieren

APA

Bao, Z., Li, H., Hu, J., Zhao, R., Yan, L., & Zheng, A. (2024). Effect of SCN1Aand SCN2A gene polymorphisms on the efficacy of valproic acid treatment in Chinese children with epilepsy. PLOS ONE, 19(6), e0304869. https://doi.org/10.1371/journal.pone.0304869

Vancouver

Bao Z, Li H, Hu J, Zhao R, Yan L, Zheng A. Effect of SCN1Aand SCN2A gene polymorphisms on the efficacy of valproic acid treatment in Chinese children with epilepsy. PLOS ONE. 2024;19(6):e0304869. doi:10.1371/journal.pone.0304869

BibTeX
@article{Bao2024,
  author = {Bao, Zejun and Li, Huanzhou and Hu, Jing and Zhao, Ru and Yan, Ling and Zheng, Aibin},
  title = {Effect of SCN1Aand SCN2A gene polymorphisms on the efficacy of valproic acid treatment in Chinese children with epilepsy},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {6},
  pages = {e0304869},
  doi = {10.1371/journal.pone.0304869}
}
Kostenlos starten →